Clinical Trial Update: Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating melphalan and filgrastim to stimulate peripheral stem cell collection in patients with multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Filgrastim (filgrastim)
• Melphalan (Melphalan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED